Nisa Investment Advisors LLC lowered its holdings in Abbott Laboratories (NYSE:ABT) by 1.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 677,357 shares of the healthcare product maker’s stock after selling 13,463 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Abbott Laboratories were worth $38,656,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Capital Research Global Investors boosted its holdings in Abbott Laboratories by 45.7% during the 2nd quarter. Capital Research Global Investors now owns 47,589,663 shares of the healthcare product maker’s stock worth $2,313,334,000 after acquiring an additional 14,918,038 shares during the last quarter. Janus Henderson Group PLC boosted its holdings in Abbott Laboratories by 3,373.9% during the 2nd quarter. Janus Henderson Group PLC now owns 7,874,473 shares of the healthcare product maker’s stock worth $382,779,000 after acquiring an additional 7,647,798 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Abbott Laboratories by 2.6% during the 2nd quarter. Vanguard Group Inc. now owns 129,786,955 shares of the healthcare product maker’s stock worth $6,308,944,000 after acquiring an additional 3,241,063 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in Abbott Laboratories by 28.6% during the 2nd quarter. Dimensional Fund Advisors LP now owns 11,722,088 shares of the healthcare product maker’s stock worth $569,830,000 after acquiring an additional 2,606,404 shares during the last quarter. Finally, Boston Partners boosted its holdings in Abbott Laboratories by 28.1% during the 2nd quarter. Boston Partners now owns 10,516,502 shares of the healthcare product maker’s stock worth $511,207,000 after acquiring an additional 2,304,467 shares during the last quarter. 70.61% of the stock is owned by institutional investors and hedge funds.
In other news, insider Sharon J. Bracken sold 2,188 shares of the company’s stock in a transaction dated Thursday, November 30th. The stock was sold at an average price of $56.12, for a total transaction of $122,790.56. Following the sale, the insider now directly owns 25,618 shares in the company, valued at $1,437,682.16. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider Alejandro D. Wellisch sold 2,153 shares of the company’s stock in a transaction dated Wednesday, November 22nd. The shares were sold at an average price of $55.86, for a total value of $120,266.58. Following the sale, the insider now owns 10,256 shares in the company, valued at $572,900.16. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 350,592 shares of company stock worth $19,426,949. Company insiders own 0.76% of the company’s stock.
Shares of Abbott Laboratories (NYSE:ABT) traded up $0.67 during trading on Friday, reaching $60.17. The company had a trading volume of 7,794,182 shares, compared to its average volume of 7,750,000. Abbott Laboratories has a fifty-two week low of $42.31 and a fifty-two week high of $64.60. The company has a market cap of $104,730.00, a PE ratio of 57.86, a P/E/G ratio of 1.81 and a beta of 1.55. The company has a quick ratio of 2.26, a current ratio of 2.69 and a debt-to-equity ratio of 0.72.
Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Wednesday, January 24th. The healthcare product maker reported $0.74 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.73 by $0.01. Abbott Laboratories had a return on equity of 13.80% and a net margin of 1.74%. The business had revenue of $7.59 billion for the quarter, compared to analysts’ expectations of $7.38 billion. During the same period in the previous year, the business posted $0.65 EPS. The firm’s quarterly revenue was up 42.3% compared to the same quarter last year. research analysts predict that Abbott Laboratories will post 2.86 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, May 15th. Investors of record on Friday, April 13th will be paid a $0.28 dividend. This represents a $1.12 dividend on an annualized basis and a yield of 1.86%. Abbott Laboratories’s dividend payout ratio is currently 107.69%.
Abbott Laboratories Profile
Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.